Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$2.72 - $9.4 $680,000 - $2.35 Million
250,000 New
250,000 $2.35 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.